World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
109
Citations
49606
World Ranking
5725
National Ranking
3078

Overview

Nyla A. Heerema is affiliated with The Ohio State University in the United States. Their research primarily focuses on the field of Medicine, with significant contributions to hematology and related subfields. Heerema's work spans several specialized areas including hematology, public health, genetics, pediatrics, and molecular biology.

Heerema has published extensively on topics related to leukemia and other blood cancers. Their main topics of research cover:

  • Acute Lymphoblastic Leukemia research
  • Acute Myeloid Leukemia Research
  • Childhood Cancer Survivors' Quality of Life
  • Chronic Lymphocytic Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Lymphoma Diagnosis and Treatment
  • Immunodeficiency and Autoimmune Disorders

Frequent collaborators of Heerema include:

  • Andrew J. Carroll
  • Meenakshi Devidas
  • Stephen P. Hunger
  • Mignon L. Loh
  • Elizabeth A. Raetz

Heerema's publications have appeared predominantly in established venues known for hematology and oncology research. Their most frequent publication venues are:

  • Blood
  • Journal of Clinical Oncology
  • Leukemia
  • Cancer Genetics
  • Blood Advances

Notable recent papers include:

  • "The genomic landscape of pediatric acute lymphoblastic leukemia," 2022, Nature Genetics
  • "Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia," 2020, Journal of Clinical Oncology
  • "Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial," 2020, Nature Medicine
  • "Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study," 2020, Clinical Cancer Research
  • "Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia," 2020, Journal of Clinical Oncology

Best Publications

  • Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

    John C. Byrd;Richard R. Furman;Steven E. Coutre;Ian W. Flinn

  • Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia

    K. G. Roberts;Y. Li;D. Payne-Turner;R. C. Harvey

  • Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.

    M Smith;D Arthur;B Camitta;A J Carroll

  • The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia

    Yu Liu;John Easton;Ying Shao;Jamie Maciaszek

  • Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

    Jennifer A Woyach;Amy S Ruppert;Nyla A Heerema;Weiqiang Zhao

  • Cytogenetics in acute leukemia

    Krzysztof Mrózek;Nyla A Heerema;Clara D Bloomfield

  • Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.

    John C. Byrd;Richard R. Furman;Steven E. Coutre;Jan A. Burger

  • Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study

    Kirk R. Schultz;W. Paul Bowman;Alexander Aledo;William B. Slayton

  • Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.

    Sarah E. M. Herman;Amber L. Gordon;Amy J. Wagner;Nyla A. Heerema

  • The genomic landscape of hypodiploid acute lymphoblastic leukemia

    Linda Holmfeldt;Lei Wei;Ernesto Diaz-Flores;Michael Walsh

  • Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia.

    Charles G Mullighan;J Racquel Collins-Underwood;Letha A A Phillips;Michael G Loudin

  • Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

    Susan O'Brien;Richard R Furman;Steven E Coutre;Jeff P Sharman

  • Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

    Kami J. Maddocks;Amy S. Ruppert;Gerard Lozanski;Nyla A. Heerema

  • Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

    Gerard Lozanski;Nyla A. Heerema;Ian W. Flinn;Lisa Smith

  • Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG)

    Kirk R. Schultz;D. Jeanette Pullen;Harland N. Sather;Jonathan J. Shuster

  • Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

    William Blum;Ramiro Garzon;Rebecca B. Klisovic;Sebastian Schwind

  • Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia

    Krzysztof Mrózek;Guido Marcucci;Deedra Nicolet;Kati S. Maharry

  • Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study.

    Brian V. Balgobind;Susana C. Raimondi;Susana C. Raimondi;Jochen Harbott;Martin Zimmermann

  • Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031.

    K. R. Schultz;A. Carroll;N. A. Heerema;W. P. Bowman

  • Rearrangement of CRLF2 in B-Progenitor and Down Syndrome Associated Acute Lymphoblastic Leukemia.

    Charles G. Mullighan;J. Racquel Collins-Underwood;Letha A Phillips;Michael G. Loudin

Frequent Co-Authors

John C. Byrd
John C. Byrd University of Pittsburgh Cancer Institute
Stephen P. Hunger
Stephen P. Hunger University of Pennsylvania
Meenakshi Devidas
Meenakshi Devidas St. Jude Children's Research Hospital
Andrew J. Carroll
Andrew J. Carroll University of Alabama at Birmingham
William L. Carroll
William L. Carroll New York University
Mignon L. Loh
Mignon L. Loh University of California, San Francisco
Naomi J. Winick
Naomi J. Winick The University of Texas Southwestern Medical Center
Elizabeth A. Raetz
Elizabeth A. Raetz New York University
Michael J. Borowitz
Michael J. Borowitz Johns Hopkins University
Brent L. Wood
Brent L. Wood University of Washington

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative and complementary degrees can expand your options in the healthcare field beyond studying Medicine in the USA. For those interested in wellness and preventive care, there are numerous online nutrition degree programs available that can lead to rewarding careers as dietitians or health coaches.

If you're focused on the administrative side of healthcare, pursuing a Master of Healthcare Administration from a CAHME-accredited MHA program can open doors to leadership roles in hospitals and health organizations.

Registered nurses seeking to advance their education without attending in-person clinicals can consider an RN to BSN online no clinicals program for greater career flexibility.

Advanced nursing professionals may be interested in the shortest post master's DNP program options, which can quickly propel them into top clinical or administrative roles.

Each of these pathways provides unique benefits and specialization opportunities, making them excellent alternatives or complements to a traditional medical degree.

Best Scientists Citing Nyla A. Heerema

Trending Scientists

Recently Published Articles